Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Blood|November 3, 2009
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetHartmut Döhner, Elihu H Estey, Sergio Amadori, et al.
Reviews in Clinical and Experimental Hematology|June 13, 2002
Acute myeloid leukemia: treatment over 60Thomas Büchner, Wolfgang Hiddemann, Wolfgang Berdel, et al.
Blood|March 1, 2012
The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotypeFriederike Schneider, Eva Hoster, Michael Unterhalt, et al.
Critical Reviews in Oncology/Hematology|October 26, 2005
Treatment of older patients with AMLThomas Büchner, Wolfgang E Berdel, Bernhard Wörmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 25, 2013
Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysisMatthias Stelljes, Utz Krug, Dietrich W Beelen, et al.
Genes, Chromosomes & Cancer|September 17, 2016
Acute myeloid leukemia with del(9q) is characterized by frequent mutations of NPM1, DNMT3A, WT1 and low expression of TLE4Tobias Herold, Klaus H Metzeler, Sebastian Vosberg, et al.
Plos One|August 31, 2016
Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk PredictionMichele Pohlen, Nils H Thoennissen, Jan Braess, et al.
European Journal of Haematology|November 9, 2017
Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclinesEva Lengfelder, Dennis Görlich, Daniel Nowak, et al.
Plos One|January 3, 2018
Correction: Patients with Acute Myeloid Leukemia Admitted to Intensive Care Units: Outcome Analysis and Risk PredictionMichele Pohlen, Nils H Thoennissen, Jan Braess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2003
Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studiesTorsten Haferlach, Claudia Schoch, Helmut Löffler, et al.
Pageof 9